Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of DUX4 Expression in Facioscapulohumeral Muscular Dystrophy and Possible Treatments

30 May 2023

Abstract excerpt

Facioscapulohumeral muscular dystrophy (FSHD) represents the third most common form of muscular dystrophy and is characterized by muscle weakness and atrophy. FSHD is caused by the altered expression of the transcription factor double homeobox 4 (DUX4), which is involved in several significantly altered pathways required for myogenesis and muscle regeneration. While DUX4 is normally silenced in the majority of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Muscle Physiology and Disorders
Share to Neurogenetic and Muscular Disorders Research
Share to RNA Research and Splicing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37298453
DOI: 10.3390/ijms24119503

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of DUX4 Expression in Facioscapulohumeral Muscular Dystrophy and Possible TreatmentsPMID 37298453Read ↗

Facioscapulohumeral Muscular Dystrophy.Semantic proximity Read ↗

Facioscapulohumeral dystrophy: activating an early embryonic transcriptional program in human skeletal muscleSemantic proximity Read ↗

Facioscapulohumeral Dystrophy: Molecular Basis and Therapeutic Opportunities.Semantic proximity Read ↗

Oligonucleotide Therapies for Facioscapulohumeral Muscular Dystrophy: Current Preclinical LandscapeSemantic proximity Read ↗

Facioscapulohumeral Muscular DystrophySemantic proximity Read ↗

Facioscapulohumeral muscular dystrophy type 2: an update on the clinical, genetic, and molecular findings.Semantic proximity Read ↗

Facioscapulohumeral muscular dystrophy: genetics, gene activation and downstream signalling with regard to recent therapeutic approaches: an updateSemantic proximity Read ↗

Consequences of epigenetic derepression in facioscapulohumeral muscular dystrophy.Semantic proximity Read ↗

A Pediatric Review of Facioscapulohumeral Muscular DystrophySemantic proximity Read ↗

Facioscapulohumeral muscular dystrophy: molecular pathological advances and future directions.Semantic proximity Read ↗

Genetic Approaches for the Treatment of Facioscapulohumeral Muscular DystrophySemantic proximity Read ↗

DUX4 at 25: how it emerged from “junk DNA” to become the cause of facioscapulohumeral muscular dystrophySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.